[Typical risks in the treatment of chronic cardiac insufficiency].
D000319:Adrenergic beta-Antagonists / Q000009:adverse effects; D000740:Anemia / Q000628:therapy; D001249:Asthma / Q000139:chemically induced; D001803:Blood Transfusion; D001919:Bradycardia / Q000139:chemically induced; D002301:Cardiac Glycosides / Q000627:therapeutic use; D002302:Cardiac Output / Q000187:drug effects; D006327:Heart Block / Q000139:chemically induced; D006333:Heart Failure / Q000188:drug therapy*; D006801:Humans; D007008:Hypokalemia / Q000139:chemically induced; D012306:Risk; D013923:Thromboembolism / Q000139:chemically induced
D000319:Adrenergic beta-Antagonists; D002301:Cardiac Glycosides
Typische Risiken bei derBehandlung der chronischen Herzinsuffizienz.